Agios Pharmaceuticals Stock News

Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, and Royalty Pharma today announced that Agios has sold its tiered, sales-bas

The company's push into thalassemia as well as sickle cell disease could transform the medication into a commercial blockbuster.

Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that clinical proof-of-concept has been established based on

Repare Therapeutics has filed to raise $100 million in an IPO, although the final figure may differ. The firm is developing treatments for solid tumors and has

Repligen develops and sells bioprocessing technologies and systems involved in the manufacturing of biological drugs. The company operates within a high growth,

Is (AGIO) Outperforming Other Medical Stocks This Year?

Technically speaking, the major U.S. benchmarks have taken flight to start June, rising amid distinctly bullish bigger-picture price action, writes Michael...

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Biohaven Pharmaceutical...

CAMBRIDGE, Jun 08, 2020 (GLOBE NEWSWIRE via COMTEX) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat...

Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Welcome to Wall Street Brunch, our preview of stock market events for investors to watch during the upcoming week. You can also catch this article a day early b

The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs. Negative clinical readouts led to some strong selling in...